Hidradenitis suppurativa (HS) is a chronic disorder of terminal follicular epithelium in the apocrine gland‐bearing areas. The long term therapy is based mainly on topical and/or systemic antibiotic use that could result in antibiotic resistance. The aim of our study was to present the real‐life experience based on the efficacy and tolerability of a novel lotion containing triethyl‐citrate, ethyl‐linoleate, and g‐peptide‐10 in the treatment of mild to moderate HS that has already shown effectiveness in acne treatment. This was an open‐label study on 30 patients of both sexes affected by HS. Patients were divided into two groups: 15 with Hurley I and 15 with Hurley II–III. The subjects were treated with the topical lotion, three‐times‐daily for eight weeks, with control at 4 (T1) and eight weeks (T2). Any other concomitant treatment (both topical and/or systemic) was avoided during study period. Improvement was observed in both Sartorius score grading system and inflammatory and noninflammatory lesion counts. The novel lotion has proved to be effective and well‐tolerated topical agent alone or in association with other topical and/or systemic tratments in HS, without side effects
Efficacy and tolerability of a lotion containing triethyl citrate, ethyl linoleate, and GT peptide‐10 in the adjuvant treatment of hidradenitis suppurativa: Real‐life data / Skroza, N; Mambrin, A; Tolino, E; Marchesiello, A; Proietti, I; Bernardini, N; Potenza, C. - In: DERMATOLOGIC THERAPY. - ISSN 1529-8019. - 31:4(2018). [10.1111/dth.12599]
Efficacy and tolerability of a lotion containing triethyl citrate, ethyl linoleate, and GT peptide‐10 in the adjuvant treatment of hidradenitis suppurativa: Real‐life data
Skroza N
Primo
Writing – Review & Editing
;Mambrin ASecondo
Writing – Original Draft Preparation
;Tolino EWriting – Original Draft Preparation
;Marchesiello AWriting – Review & Editing
;Proietti IWriting – Review & Editing
;Bernardini NPenultimo
Writing – Review & Editing
;Potenza CUltimo
Supervision
2018
Abstract
Hidradenitis suppurativa (HS) is a chronic disorder of terminal follicular epithelium in the apocrine gland‐bearing areas. The long term therapy is based mainly on topical and/or systemic antibiotic use that could result in antibiotic resistance. The aim of our study was to present the real‐life experience based on the efficacy and tolerability of a novel lotion containing triethyl‐citrate, ethyl‐linoleate, and g‐peptide‐10 in the treatment of mild to moderate HS that has already shown effectiveness in acne treatment. This was an open‐label study on 30 patients of both sexes affected by HS. Patients were divided into two groups: 15 with Hurley I and 15 with Hurley II–III. The subjects were treated with the topical lotion, three‐times‐daily for eight weeks, with control at 4 (T1) and eight weeks (T2). Any other concomitant treatment (both topical and/or systemic) was avoided during study period. Improvement was observed in both Sartorius score grading system and inflammatory and noninflammatory lesion counts. The novel lotion has proved to be effective and well‐tolerated topical agent alone or in association with other topical and/or systemic tratments in HS, without side effectsFile | Dimensione | Formato | |
---|---|---|---|
Skroza_Dermatologic_therapy_2018.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
607.03 kB
Formato
Adobe PDF
|
607.03 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.